Sovleplenib clinical trials
Also written HMPL-523.
Includes 1 study of Sovleplenib acetate.
How each study uses sovleplenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 0
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses sovleplenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaActive, not recruitingPhase 2/3HutchmedNCT05535933Written as HMPL-523(300mg PO QD)
- Phase III Study on HMPL-523 for Treatment of ITPCompletedPhase 3HutchmedNCT05029635Written as HMPL-523
- An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With LymphomaTerminatedPhase 1HutchmedNCT03779113Written as HMPL-523
- Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate TabletsCompletedPhase 1HutchmedNCT07348133Written as HMPL-523
- Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in HumansCompletedPhase 1HutchmedNCT07331194Written as HMPL-523 Acetate Tablets (Test Formulation)
- The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)WithdrawnPhase 1HutchmedNCT06291415Written as HMPL-523
- The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia PatientsCompletedPhase 1Hutchison Medipharma LimitedNCT03951623Written as HMPL-523
- Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese SubjectsCompletedPhase 1HutchmedNCT05781906Written as HMPL-523
- A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell NeoplasmsCompletedPhase 1Hutchison Medipharma LimitedNCT02857998Written as HMPL-523
- A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different ManufacturersCompletedEarly Phase 1Hutchison Medipharma LimitedNCT05318820Written as HMPL-523
- HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer StudyCompletedPhase 1HutchmedNCT05720767Written as HMPL-523
- HMPL-523 Food Effect and Proton Pump Inhibitor StudyCompletedPhase 1HutchmedNCT05571787Written as HMPL-523
- A Study of HMPL-523 in Relapsed or Refractory Hematologic MalignanciesStatus unknownPhase 1Hutchison Medipharma LimitedNCT02503033Written as HMPL-523
- Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid LeukemiaTerminatedPhase 1Hutchison Medipharma LimitedNCT03483948Written as HMPL-523
- A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523CompletedPhase 1Hutchison Medipharma LimitedNCT02105129Written as HMPL-523
Codes
What other systems call sovleplenib · ClinicalTrials.gg INT015846
- UNII (FDA) 9CL6353KHOSOVLEPLENIBOne source FDA
- NCI Thesaurus C123912SovleplenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9CL6353KHO | SOVLEPLENIB | One source FDA |
| NCI Thesaurus | C123912 | Sovleplenib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.